<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Taurolidine and heparin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Taurolidine and heparin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Taurolidine and heparin: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="143508" href="/d/html/143508.html" rel="external">see "Taurolidine and heparin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58848465"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous;</li>
<li>
                        Anticoagulant</li></ul></div>
<div class="block doa drugH1Div" id="F58875355"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="efef87aa-1fcf-4ce9-a06d-60af3ed92859">Catheter-related bloodstream infection, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catheter-related bloodstream infection, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only indicated for patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracatheter:</b> Instill a sufficient volume of solution (containing heparin 1,000 units/mL and taurolidine 13.5 mg/mL) into each catheter lumen at the conclusion of each HD session; prior to initiation of the next HD session, aspirate and discard solution from the catheter. <b>Note:</b> Not intended for systemic administration or for use as a catheter lock flush.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58875357"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as taurolidine/heparin is not intended for systemic administration.</p></div>
<div class="block doha drugH1Div" id="F58875358"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as taurolidine/heparin is not intended for systemic administration.</p></div>
<div class="block doe drugH1Div" id="F58875356"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58859593"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. Also see Heparin monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7%), vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (7%), thrombocytopenia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Paresthesia</p></div>
<div class="block coi drugH1Div" id="F58848466"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to taurolidine, heparin, the citrate excipient, pork products, or any component of the formulation; known heparin-induced thrombocytopenia.</p></div>
<div class="block war drugH1Div" id="F58875351"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin-induced thrombocytopenia: Heparin-induced thrombocytopenia (HIT), a serious antibody-mediated reaction resulting from irreversible aggregation of platelets, may occur. Patients who develop HIT may be at risk of developing a new thrombus (heparin-induced thrombocytopenia with thrombosis [HITT]). Discontinue therapy and consider alternatives if platelet count falls below 100,000/mm<sup>3</sup>, there is a &gt;50% reduction in platelet count from baseline, and/or thrombosis develops while on heparin therapy. Onset of HIT or HITT is usually delayed (5 to 10 days after exposure in heparin-naive individuals) and can occur up to several weeks after discontinuation of heparin. “Rapid onset” HIT can occur within 24 hours of heparin initiation, especially in patients with recent heparin exposure within the previous 100 days. Use with extreme caution (for a limited duration) or avoid use in patients with history of HIT, especially if administered within 100 days of a HIT episode (Dager 2007; Warkentin 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions may occur. Discontinue therapy and institute supportive measures if hypersensitivity occurs.</p></div>
<div class="block prod-avail drugH1Div" id="F58848467"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Defencath: FDA approved November 2023; anticipated availability is currently unknown.</p></div>
<div class="block adm drugH1Div" id="F58875359"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intracatheter: </b>Not intended for systemic administration. Instill into each central venous catheter lumen at the conclusion of each hemodialysis (HD) session. Prior to initiation of the next HD session, aspirate taurolidine and heparin from the catheter and discard; do <b>not</b> use as a catheter lock flush product.</p></div>
<div class="block use drugH1Div" id="F58848469"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Catheter-related bloodstream infection, prevention:</b> To reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: The safety and effectiveness of taurolidine and heparin have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.</p></div>
<div class="block cyt drugH1Div" id="F58898244"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58898241"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrogen Peroxide: Taurolidine may enhance the adverse/toxic effect of Hydrogen Peroxide. Specifically, concomitant use of taurolidine and hydrogen peroxide may increase the risk of metabolic acidosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Povidone-Iodine (Topical): Taurolidine may enhance the adverse/toxic effect of Povidone-Iodine (Topical). Specifically, concomitant use of taurolidine and povidone-iodine may increase the risk of metabolic acidosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Hypochlorite: Taurolidine may enhance the adverse/toxic effect of Sodium Hypochlorite. Specifically, concomitant use of taurolidine and sodium hypochlorite may increase the risk of metabolic acidosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May diminish the therapeutic effect of Taurolidine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F58875349"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Not intended for systemic administration; maternal use as a catheter lock solution is not expected to result in fetal exposure.</p></div>
<div class="block brc drugH1Div" id="F58875350"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if heparin or taurolidine are present in breast milk following use as a catheter lock solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Not intended for systemic administration; breastfeeding following use as a catheter lock solution is not expected to provide exposure to an infant via breast milk.</p></div>
<div class="block pha drugH1Div" id="F58875354"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Taurolidine is a thiadiazinane antimicrobial derived from the amino acid taurine. Taurolidine and its metabolites damage microbial cell walls and inhibit adherence of microorganisms to biological surfaces.</p>
<p style="text-indent:-2em;margin-left:2em;">Heparin potentiates the action of antithrombin III and thereby inactivates thrombin (as well as other coagulation factors IXa, Xa, XIa, XIIa, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17381384">
<a name="17381384"></a>Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. <i>Pharmacotherapy</i>. 2007;27(4):564-587. doi:10.1592/phco.27.4.564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/taurolidine-and-heparin-drug-information/abstract-text/17381384/pubmed" id="17381384" target="_blank">17381384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Defencath.1">
<a name="Defencath.1"></a>Defencath (taurolidine and heparin) [prescribing information]. Berkeley Heights, NJ: CorMedix Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320387">
<a name="11320387"></a>Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia.<i> N Engl J Med</i>. 2001;344(17):1286-1292. doi:10.1056/NEJM200104263441704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/taurolidine-and-heparin-drug-information/abstract-text/11320387/pubmed" id="11320387" target="_blank">11320387</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 143454 Version 7.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
